Deborah Knobelman - 01 Feb 2024 Form 4 Insider Report for Senti Biosciences, Inc. (SNTI)

Role: Chief Financial Officer, Head of Corporate Development
Signature: /s/ Mike Rhee, attorney-in-fact
Issuer symbol: SNTI
Transactions as of: 01 Feb 2024
Net transactions value: $0
Form type: 4
Filing time: 02 Feb 2024, 17:24:38 UTC
Previous filing: 02 Feb 2023
Next filing: 04 Jun 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SNTI	Common Stock	Award	$0	+101,000	+337%	$0.000000	131,000	01 Feb 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SNTI	Stock Option (Right to Buy)	Award	$0	+152,000		$0.000000	152,000	01 Feb 2024	Common Stock	152,000	$0.4600	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares reported in this transaction represent restricted stock units ("RSUs") issued under the Senti Biosciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. All of the shares underlying the award vest in three substantially equal annual installments over three years from February 1, 2024, subject to the reporting person's continued service through the applicable vesting date.
F2	The shares underlying this option vest in 48 substantially equal monthly installments over four years from February 1, 2024, subject to the reporting person's continued service through the applicable vesting date.

Content

The shares reported in this transaction represent restricted stock units ("RSUs") issued under the Senti Biosciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. All of the shares underlying the award vest in three substantially equal annual installments over three years from February 1, 2024, subject to the reporting person's continued service through the applicable vesting date.

The shares underlying this option vest in 48 substantially equal monthly installments over four years from February 1, 2024, subject to the reporting person's continued service through the applicable vesting date.